Please assess the completion status of the following clinical trial:

Trial Title: Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients, ≥ 18 years of age~2. Documented definitive diagnosis of CD33 positive AML (according to standard of care testing) in~   * 2a. Patients having received standard induction chemotherapy: either refractory to standard induction treatment, or is relapsed within 6 months after achieving 1st CR, or relapsed later than 6 months after 1st CR and refractory to standard salvage regimen, or relapse after ≥ 2nd CR and not eligible for curative treatment (i.e. allogeneic stem cell transplantation)~  * 2b. Patients not eligible for standard induction chemotherapy: either refractory or progressive after at least 1 cycle of demethylating agents~3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1~4. Life expectancy of at least 2 months~5. Adequate renal and hepatic laboratory assessments:~6. Adequate cardiac function, i.e. left ventricular ejection fraction (LVEF) of ≥ 45% as assessed by transthoracal two-dimensional echocardiography~7. A female of childbearing potential may be enrolled providing she has a negative pregnancy test at screening visit and is routinely using a highly effective method of birth control (pearl index of ≤ 1 required) resulting in a low failure rate (e.g. hormonal contraception, intrauterine device, total sexual abstinence or sterilization) until 3 months from the last study drug administration. Male patients must also practice a highly effective method of birth control.~8. Able to give written informed consent~9. Weight ≥ 45 kg~Exclusion Criteria:~1. Acute promyelocytic leukemia (t15;17)~2. Manifestation of AML in central nervous system~3. Leukocytosis \> 10 Gpt/L~4. Cardiac disease: i.e. heart failure NYHA III or IV; unstable coronary artery disease (Myocardial Infarction more than 6 months prior to study entry is permitted); serious cardiac ventricular arrhythmias requiring anti-arrhythmic therapy~5. Patients undergoing renal dialysis~6. Pulmonary disease with clinical relevant hypoxia (need for continuous oxygen inhalation)~7. Active central nervous diseases (e.g. parkinson, multiple sclerosis, epilepsy) and stroke within last 6 months~8. Active infectious disease considered by investigator to be incompatible with protocol~9. Allogeneic stem cell transplantation within last three months or GvHD requiring immune-suppressive therapy~10. Major surgery within 28 days prior to start of study medication~11. Other malignancy requiring active therapy but adjuvant endocrine therapy is allowed~12. Checkpoint inhibitors und CD33 targeting agents within 8 weeks prior to start of trial medication~13. Autoimmune diseases requiring systemic steroids or other systemic immunosuppressants~14. Treatment with any investigational drug substance or experimental therapy within 4 weeks prior to start of trial medication or 5 half lives of the substance prior to start of trial medication~15. Pregnant or breastfeeding women~16. Psychologic disorders, drug and/or significant active alcohol abuse~17. Known history of human immunodeficiency virus (HIV) or active/chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV)~18. Known hypersensitivity to GEM333 excipients~19. Evidence suggesting that the patient is not likely to follow the study protocol (e.g. lacking compliance)~20. Incapability of understanding purpose and possible consequences of the trial~21. Patients who should not be included according to the opinion of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GEM333 (Type: EXPERIMENTAL): application of GEM333, a CD33 targeted bispecific antibody engaging T-cells

Based on this trial design, predict the completion outcome and termination type (if applicable).